Pharmafile Logo

Blog: The Future of Food Allergy? The Emergence of Targeted Allergy Treatments

May 2, 2019 | Nutritions, Pharma, allergy, healthcare 

Research Analyst Rachel Arthurs explores how public exposure to the complications of food allergy has affected attitudes toward treatment.

In recent years, there has been a noticeable shift in the increased public awareness of allergy-related complications both within the United Kingdom and globally. In 2010, Allergy UK estimated that at least 44% of British adults were currently suffering from at least one allergy, a statistic that only continues to rise steadily each year. In the United States, Statista reported that approximately 20% of American adults in 2017 were suffering from an allergy or food intolerance. The growing interest in allergy shown by the British public was further amplified by the widespread outrage in 2017, following an incident in which a teenage customer of a popular British sandwich chain experienced anaphylaxis as a direct result of inadequate allergen labelling. This is not an isolated incident, but a constant fear and source of anxiety for allergy sufferers all over the world.

Read the full blog here: https://bit.ly/2VCPwf0

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Free Thinking: Behavioural economics

Our Free Thinking white paper asks, does behavioural economic theory have a role to play in pharmaceutical market research?

Article: The Colombia Conundrum

Published in eye for pharma 30 January by Marc Yates

Ageing in China: The Implications for Healthcare

Published in eye for pharma 12 December by Marc Yates

Exploring MINT: Part 4 – Turkey

In the fourth and final of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in...

Getting to grips with Russia’s healthcare market

As a non-Russian, trying to understand the complexities of the multiple overlapping levels of Russia’s healthcare system can be baffling at times. Information is often inaccessible or data simply doesn't...

Exploring MINT: Part 3 – Nigeria

In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria.

Exploring MINT: Part 2 – Indonesia

In the second of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Indonesia, with...

Free Thinking: Leveraging the ASEAN Market

If you can only research one ASEAN market, which one do you choose?Our Free Thinking paper investigates the opportunities for pharma in ASEAN and outlines the factors you need to...

Free Thinking: Biosimilars: Friend or foe to healthcare?

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.